Cardinal Capital Management Inc (North Carolina)’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.28M Sell
62,101
-69
-0.1% -$3.65K 0.4% 79
2026
Q1
$3.46M Buy
62,170
+426
+0.7% +$23.1K 0.45% 77
2025
Q4
$3.05M Buy
61,744
+251
+0.4% +$11.7K 0.4% 78
2025
Q3
$2.68M Buy
61,493
+1,327
+2% +$51.8K 0.37% 85
2025
Q2
$2.34M Buy
60,166
+1,594
+3% +$60.9K 0.34% 88
2025
Q1
$2.29M Buy
58,572
+244
+0.4% +$8.93K 0.36% 87
2024
Q4
$1.99M Buy
58,328
+1,956
+3% +$70.4K 0.31% 92
2024
Q3
$2.33M Buy
56,372
+808
+1% +$33.1K 0.36% 85
2024
Q2
$2.16M Buy
55,564
+1,390
+3% +$58.5K 0.36% 82
2024
Q1
$2.34M Buy
54,174
+4,332
+9% +$179K 0.38% 81
2023
Q4
$1.86M Buy
49,842
+226
+0.5% +$8.11K 0.35% 84
2023
Q3
$1.82M Buy
49,616
+948
+2% +$33.6K 0.37% 82
2023
Q2
$1.75M Sell
48,668
-26,655
-35% -$956K 0.35% 83
2023
Q1
$2.69M Buy
75,323
+43,599
+137% +$1.53M 0.56% 58
2022
Q4
$1.11M Buy
31,724
+1,112
+4% +$37K 0.24% 105
2022
Q3
$901K Sell
30,612
-1,370
-4% -$51.9K 0.21% 107
2022
Q2
$1.74M Buy
31,982
+265
+0.8% +$14.6K 0.4% 72
2022
Q1
$1.73M Buy
31,717
+1,273
+4% +$69.1K 0.35% 84
2021
Q4
$1.68M Sell
30,444
-27
-0.1% -$1.41K 0.33% 86
2021
Q3
$1.46M Sell
30,471
-8,123
-21% -$408K 0.32% 87
2021
Q2
$1.92M Buy
38,594
+19,735
+105% +$948K 0.41% 76
2021
Q1
$841K Buy
18,859
+1,363
+8% +$61.9K 0.19% 118
2020
Q4
$805K Buy
17,496
+790
+5% +$36.3K 0.19% 112
2020
Q3
$786K Sell
16,706
-522
-3% -$26.2K 0.22% 97
2020
Q2
$878K Sell
17,228
-46
-0.3% -$2.36K 0.25% 96
2020
Q1
$818K Buy
17,274
+60
+0.3% +$3.2K 0.27% 90
2019
Q4
$1.01M Sell
17,214
-90
-0.5% -$5.01K 0.26% 97
2019
Q3
$923K Buy
17,304
+250
+1% +$12.9K 0.26% 97
2019
Q2
$853K Buy
17,054
+72
+0.4% +$3.61K 0.24% 101
2019
Q1
$887K Buy
16,982
+184
+1% +$9.19K 0.25% 98
2018
Q4
$802K Buy
+16,798
New +$827K 0.26% 95

Other funds holding GSK

Cardinal Capital Management Inc (North Carolina)'s GSK Position: Q2 2026 in Review

Cardinal Capital Management Inc (North Carolina) reduced its GSK (GSK) stake by 0.11% in Q2 2026, selling an estimated $3.65K and leaving 62,101 shares worth $3.28M. The position accounts for 0.4% of the portfolio, ranked #79.

Cardinal Capital Management Inc (North Carolina) first reported a position in GSK in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.46M in Q1 2026. 573 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Cardinal Capital Management Inc (North Carolina) held 62,101 shares of GSK worth $3.28M as of Q2 2026.
  • Cardinal Capital Management Inc (North Carolina) sold 69 GSK shares in Q2 2026, an estimated $3.65K.
  • GSK made up 0.4% of Cardinal Capital Management Inc (North Carolina)'s portfolio in Q2 2026, its #79 holding.
  • Cardinal Capital Management Inc (North Carolina) first reported a position in GSK in Q4 2018 and has held it in 31 quarters since.
  • Cardinal Capital Management Inc (North Carolina)'s GSK position peaked at $3.46M in Q1 2026.
  • 573 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Cardinal Capital Management Inc (North Carolina)'s 13F filing for Q2 2026, filed 21 Jul 2026.